Welcome to our dedicated page for PROPANC BIOPHARMA news (Ticker: PPCB), a resource for investors and traders seeking the latest updates and insights on PROPANC BIOPHARMA stock.
Propanc Biopharma, Inc. (symbol: PPCB) is a development-stage healthcare company with a focus on creating innovative cancer treatments. Based in Camberwell, Australia, the company was founded in 2007 and initially known as Propanc Health Group Corporation before it rebranded in April 2017.
Propanc Biopharma's core business centers on developing therapies for pancreatic, ovarian, and colorectal cancers. Its flagship product, PRP, is in the preclinical phase of development. PRP is a unique formulation designed to enhance the anti-cancer effects of multiple enzymes that work together synergistically. This approach aims to provide a more effective cancer treatment compared to traditional methods.
The company is actively engaged in research and development, with a notable collaboration with the University of Jaén. This partnership is focused on initiating the POP1 joint drug discovery program, which aims to further the development of innovative cancer treatments.
Propanc Biopharma is committed to advancing its research and product pipeline, aiming to bring new cancer therapies to market. As a development-stage company, its financial condition and funding are pivotal to its continued progress in research and clinical trials. The company frequently updates stakeholders on its latest developments and milestones.
Stay informed about Propanc Biopharma's latest news and progress to get insights into their ongoing projects and achievements.
Propanc Biopharma (OTC Pink: PPCB) announced significant interest in their scientific publications on proenzymes cancer treatment. Two peer-reviewed articles reached 10 citations and 4,500 reads in August 2024. The first article, published in Scientific Reports, demonstrates the effectiveness of proenzymes in suppressing pancreatic Cancer Stem Cells. The second article highlights the anti-tumor efficacy of pancreatic proenzymes, particularly for pancreatic and ovarian cancers.
A clinical study led by Dr. Kenyon showed that 41.3% of late-stage cancer patients treated with proenzymes had significantly longer survival times than expected. With global market projections for pancreatic cancer drugs at $6.93 billion by 2030 and ovarian cancer drugs at $13.9 billion by 2029, Propanc Biopharma aims to advance its lead asset, PRP, into early-stage clinical development to address the pressing need for new therapies with fewer side effects.
Propanc Biopharma (OTC Pink: PPCB) has received a Notice of Allowance for its 'Proenzyme Composition' patent from the Canadian Intellectual Property Office. This patent broadly covers high dose and high ratio claims for future clinical doses of PRP, the company's lead asset for treating recurring and metastatic cancer. It's the second Canadian patent allowed or granted, part of Propanc's 93-patent portfolio filed in major jurisdictions. The patent is important for future clinical dosage ranges as Propanc advances towards a Phase 1 First-In-Human study in advanced cancer patients with solid tumors. PRP targets the global metastatic cancer treatment market, projected to reach $111.2 Billion by 2027. The patent has been granted in Europe, Japan, and South East Asia, and is under examination in the US.
Propanc Biopharma (OTC Pink: PPCB) announces that its lead asset, PRP, could potentially solve the problem affecting response rates of immune checkpoint inhibitors in treating PD-L1-High solid tumors. Dr. Julian Kenyon, CSO, predicts that pretreatment with PRP could reverse the promotion of epithelial to mesenchymal transition (EMT) pathways induced by PD-L1, which are responsible for tumor growth and metastasis.
The Immune Checkpoint Inhibitors Market, valued at $47.22 Billion in 2023, is expected to reach $158.26 Billion by 2031. However, response rates for most solid tumors range only between 15-30%. A recent study in the British Journal of Cancer suggests that EMT induced by tumor cell-intrinsic PD-L1 signaling predicts poor response to immune checkpoint inhibitors in PD-L1-High lung cancer.
Dr. Kenyon believes PRP could enable PD-L1 non-responders to become responders by inducing cell differentiation in cancer cells, reversing EMT pathways, and reducing metastatic potential.
Propanc Biopharma, a biopharmaceutical company, announced receiving a Certificate of Grant for its “proenzymes composition” patent from the Japanese Patent Office, marking its fourth Japanese patent. This patent covers dosing regimen claims for PRP, the company's lead asset, advancing to clinical development. Additionally, the Intellectual Property of Malaysia granted a patent for a cancer treatment using trypsinogen and chymotrypsinogen, the company's third patent in Malaysia. Propanc's intellectual property portfolio now includes 93 patents worldwide for using PRP against solid tumors. Japan's pharmaceutical market, projected to reach $46.36 billion in 2024, is a key market for Propanc. The company aims to advance PRP into a Phase 1b clinical study, targeting and eradicating cancer stem cells without severe side effects.
FAQ
What is the current stock price of PROPANC BIOPHARMA (PPCB)?
What is the market cap of PROPANC BIOPHARMA (PPCB)?
What does Propanc Biopharma, Inc. specialize in?
What is PRP?
Where is Propanc Biopharma, Inc. located?
What significant partnership does Propanc Biopharma have?
When was Propanc Biopharma founded?
What was Propanc Biopharma's former name?
When did Propanc Biopharma change its name?
What is the focus of the POP1 joint drug discovery program?
Why is PRP important?
How does Propanc Biopharma update its stakeholders?
